Cas no 59198-70-8 (Diflucortolone valerate)

Diflucortolone valerate is a synthetic corticosteroid with potent anti-inflammatory, antipruritic, and vasoconstrictive properties. It is commonly used in dermatological formulations to treat inflammatory skin conditions such as eczema, psoriasis, and contact dermatitis. The valerate ester enhances its lipophilicity, improving skin penetration and localized efficacy while minimizing systemic absorption. Its high glucocorticoid receptor affinity ensures rapid onset of action and sustained therapeutic effects at low concentrations. Diflucortolone valerate is particularly effective in managing severe or resistant dermatoses due to its strong immunosuppressive and anti-proliferative activity. It is available in various topical formulations, including creams and ointments, tailored to different clinical needs.
Diflucortolone valerate structure
Diflucortolone valerate structure
Product Name:Diflucortolone valerate
CAS No:59198-70-8
MF:C27H36F2O5
MW:478.568555831909
CID:57382
PubChem ID:91670
Update Time:2025-05-19

Diflucortolone valerate Chemical and Physical Properties

Names and Identifiers

    • Diflucortolone valerate
    • 6a,9-Difluoro-11b,21-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione 21-valerate
    • Diflucortolone 21-Valerate
    • DIFLUCORTOLONE VALERAT
    • (6α,11β,16α-)-6,9-Difluoro-11-hydroxy-16-methyl-21-[(1-oxopentyl)oxy]pregna-1,4-diene-3,20-dione
    • BRN 2030579
    • Q10860261
    • 6-alpha,9-Difluoro-11-beta-hydroxy-16-alpha-methyl-21-valeryloxy-1,4-pregnadiene-3,20-dione
    • Afusona (TN)
    • [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17S)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] pentanoate
    • NS00055473
    • Q-200986
    • DIFLUCORTOLONE VALERATE [WHO-DD]
    • E86978
    • Difluocortolone valerianate
    • Diflucortolone valerate Assay Standard
    • UNII-1A63Z067C8
    • DIFLUCORTOLONE 21-VALERATE [MI]
    • Temetex
    • HY-U00058
    • Diflucortolone valerate impurity standard
    • Diflucortolonvalerianat
    • DTXSID1048598
    • CAS-59198-70-8
    • Diflucortolonevalerate
    • DIFLUCORTOLONE VALERATE [MART.]
    • Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-21-((1-oxopentyl)oxy)-, (6-alpha,11-beta,16-alpha)-
    • 1A63Z067C8
    • Tox21_112929_1
    • Diflucortolone valerate (JP17)
    • Tox21_112929
    • Nerisone
    • NCGC00263574-01
    • NCGC00183100-01
    • Afusona
    • Nerisona
    • Texmeten
    • CHEMBL2358130
    • CCG-269528
    • 59198-70-8
    • 6alpha,9-Difluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-valerate
    • Difluocortolone Valerate
    • DTXCID1028524
    • CHEBI:31484
    • Diflucortolonvalerianat [German]
    • EINECS 261-655-8
    • 6-alpha,9-Difluoro-11-beta-hydroxy-21-valeryloxy-16-alpha-methyl-1,4-pregnadiene-3,20-dione
    • AKOS015901782
    • s5414
    • D01764
    • Diflucortolone valerate [JAN]
    • CS-0021944
    • SCHEMBL3015
    • BAY-866146
    • 6alpha,9-Difluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-pentanate
    • HHJIUUAMYGBVSD-YTFFSALGSA-N
    • DA-62867
    • BAY866146
    • DIFLUCORTOLONE VALERATE (MART.)
    • Inchi： 1S/C27H36F2O5/c1-5-6-7-23(33)34-14-21(31)24-15(2)10-17-18-12-20(28)19-11-16(30)8-9-26(19,4)27(18,29)22(32)13-25(17,24)3/h8-9,11,15,17-18,20,22,24,32H,5-7,10,12-14H2,1-4H3/t15-,17+,18+,20+,22+,24-,25+,26+,27+/m1/s1
    • InChI Key： HHJIUUAMYGBVSD-YTFFSALGSA-N
    • SMILES： F[C@@]12[C@]3(C=CC(C=C3[C@H](C[C@H]1[C@@H]1C[C@@H](C)[C@H](C(COC(CCCC)=O)=O)[C@@]1(C)C[C@@H]2O)F)=O)C

Computed Properties

  • Exact Mass: 478.25300
  • Monoisotopic Mass: 478.253
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 7
  • Heavy Atom Count: 34
  • Rotatable Bond Count: 7
  • Complexity: 943
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 9
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 4.2
  • Topological Polar Surface Area: 80.7A^2

Experimental Properties

  • Density: 1.1227 (estimate)
  • Melting Point: 220 oC
  • Boiling Point: 578.5 °C at 760 mmHg
  • Flash Point: 578.5 °C at 760 mmHg
  • Refractive Index: 1.538
  • PSA: 80.67000
  • LogP: 4.46990
  • Specific Rotation: D22 +100.8° (dioxane)

Diflucortolone valerate Security Information

  • Toxicity：Approx LD50 in mice, rats: >4, 3.1 g/kg orally; 180, 13 mg/kg s.c.; 450, 98 mg/kg i.p. (Gunzel).
  • Storage Condition：2-8°C

Diflucortolone valerate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
X78665-5mg
Diflucortolone 21-Valerate
 59198-70-8 BR
5mg
 ￥308.0 2023-09-05
TRC
D445620-2.5mg
Diflucortolone 21-Valerate
 59198-70-8
2.5mg
 $ 119.00 2023-09-07
TRC
D445620-10mg
Diflucortolone 21-Valerate
 59198-70-8
10mg
 $ 232.00 2023-09-07
TRC
D445620-50mg
Diflucortolone 21-Valerate
 59198-70-8
50mg
 $ 1041.00 2023-09-07
ChemScence
CS-0021944-5mg
Diflucortolone valerate
 59198-70-8 99.48%
5mg
 $90.0 2022-04-27
MedChemExpress
HY-U00058-5mg
Diflucortolone valerate
 59198-70-8 99.90%
5mg
 ￥692 2025-04-16
MedChemExpress
HY-U00058-10mM*1mLinDMSO
Diflucortolone valerate
 59198-70-8 99.48%
10mM*1mLinDMSO
 ￥990 2022-05-18
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
D872991-5mg
Diflucortolone 21-valerate
 59198-70-8 BR
5mg
 ￥1,198.00 2022-01-13
FUJIFILM
047-32923-250mg
Diflucortolone Valerate
 59198-70-8
250mg
 JPY 73,800 2021-11-29
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
D304084-5mg
Diflucortolone valerate
 59198-70-8 98%
5mg
 ￥649.90 2023-09-03

Diflucortolone valerate Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:59198-70-8)Diflucortolone 21-Valerate
Order Number:LE15890
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:13
Price ($):discuss personally

Diflucortolone valerate Related Literature

Additional information on Diflucortolone valerate

Professional Introduction to Diflucortolone Valerate (CAS No. 59198-70-8)

Diflucortolone valerate, a synthetic corticosteroid derivative, is widely recognized for its potent anti-inflammatory and immunosuppressive properties. With the CAS number 59198-70-8, this compound has garnered significant attention in the field of pharmaceutical chemistry due to its unique pharmacological profile. The molecule is characterized by a valerate ester group, which enhances its lipophilicity and bioavailability, making it an effective therapeutic agent for various inflammatory and autoimmune conditions.

The chemical structure of diflucortolone valerate consists of a fluorinated 16α-hydroxyprednisolone backbone, which is a key factor in its high efficacy. This structural feature contributes to its ability to bind strongly to glucocorticoid receptors, thereby modulating the transcription of genes involved in inflammation and immune responses. The compound's mechanism of action is closely related to its ability to inhibit the production of pro-inflammatory cytokines and enzymes, such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).

In recent years, diflucortolone valerate has been extensively studied for its potential applications in treating a range of medical conditions. One of the most notable areas of research has been its use in dermatology. Studies have demonstrated that topical formulations of diflucortolone valerate are highly effective in managing moderate to severe cases of eczema and psoriasis. The compound's ability to reduce erythema, scaling, and pruritus makes it a valuable option for patients who have not responded well to other topical corticosteroids.

Moreover, diflucortolone valerate has shown promise in the treatment of allergic rhinitis and asthma. Clinical trials have indicated that intranasal sprays containing this compound can significantly reduce nasal symptoms such as congestion, runny nose, and sneezing. Additionally, inhalation formulations have been found to improve lung function and reduce airway hyperresponsiveness in patients with asthma. These findings highlight the compound's potential as a therapeutic option for respiratory conditions driven by inflammation.

The pharmacokinetic properties of diflucortolone valerate also contribute to its clinical efficacy. The valerate ester group enhances the compound's absorption through the skin and respiratory tract, allowing for targeted delivery to affected areas. This property is particularly beneficial in topical applications, where rapid absorption is essential for achieving therapeutic levels. Furthermore, the compound exhibits a moderate duration of action, which allows for less frequent dosing compared to some other corticosteroids.

Recent advancements in drug delivery systems have further expanded the applications of diflucortolone valerate. Nanoparticle-based formulations have been developed to improve bioavailability and reduce local side effects such as skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression. These innovations are particularly important for long-term treatment regimens, where minimizing systemic exposure is crucial.

Research into the molecular mechanisms underlying the anti-inflammatory effects of diflucortolone valerate has also yielded valuable insights. Studies have revealed that the compound activates multiple signaling pathways involved in inflammation regulation. For instance, it has been shown to inhibit the nuclear factor kappa B (NF-κB) pathway, a key regulator of inflammatory gene expression. Additionally, diflucortolone valerate modulates the activity of Janus kinases (JAKs), which are essential for signal transduction in immune cells.

The safety profile of diflucortolone valerate has been carefully evaluated in numerous clinical studies. While like all corticosteroids, it can cause local side effects such as burning or stinging upon application, systemic adverse effects are generally rare when used at appropriate doses. Long-term use may be associated with increased susceptibility to infections or adrenal suppression, but these risks are mitigated by careful dosing and monitoring under medical supervision.

Future research directions for diflucortolone valerate include exploring its potential in combination therapies with other anti-inflammatory agents. This approach could enhance therapeutic outcomes while reducing the risk of side effects associated with high-dose monotherapy. Additionally, studies are ongoing to investigate the compound's efficacy in treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

In conclusion, diflucortolone valerate (CAS No. 59198-70-8) is a versatile corticosteroid with significant therapeutic potential across multiple medical disciplines. Its unique pharmacological properties make it an effective treatment option for inflammatory and autoimmune conditions without compromising patient safety when used appropriately.

59198-70-8 (Diflucortolone valerate) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:59198-70-8)Diflucortolone 21-Valerate
LE15890
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email